Autopsy report · NCT01740401

CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma

“Primary Endpoint not met”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 2 years 2 months before it stopped.
• 10 participants enrolled.
• Results were posted on the registry 2 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Icahn School of Medicine at Mount Sinai

Sponsor type

University, hospital or other

Conditions

Melanoma

Interventions

Cyclophosphamide

Participants

10

Sites

1

Countries

United States

Trials that died the same way

• Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
  “primary endpoint was not met” (98% match in meaning)
• Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
  “Primary endpoint not achieved” (93% match in meaning)
• Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms
  “Primary Endpoint met” (91% match in meaning)
• Cytokines and the Risk of Infection in Liver Cirrhosis
  “Finding to be unable to reach the primary endpoint” (84% match in meaning)
• A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
  “Primary (safety) endpoint reached” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.